XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of multiple myeloma (MM) and hepatitis C. The Company’s lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL’s second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company on March 20, 2008.

Metagenics, Inc., doing business as Ethical Nutrients, manufactures and distributes medical foods and nutraceuticals to healthcare practitioners. The company offers FirstLine Therapy programs for the prevention and management of chronic conditions, including diabetes, cardiovascular disease, and arthritis. It distributes its products in North America, South America, Europe, and Asia. The company was founded in 1983 and is headquartered in San Clemente, California with research and development centers in Gig Harbor, Washington; and Ithaca, New York. It has manufacturing facilities in Gig Harbor, Washington. As of September 11, 2009, Metagenics, Inc. operates as a subsidiary of Alticor Inc.

Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

Cortex Pharmaceuticals develops drugs to treat neurodegenerative and psychiatric disorders. Its research focuses on the AMPA receptor, which facilitates communication between nerve cells; the firm's Ampakine compounds may enhance this receptor's activity. Its lead drug candidate is CX717, which it is developing for a number of indications including respiratory depression (a potentially fatal side effect of some anesthetics and post-surgical painkillers), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and daytime sleepiness. The firm believes Ampakine drugs may also be helpful in treating a variety of other brain-related disorders, including depression, autism, and Huntington's disease.

Inhibitex, Inc. was founded in 1994 and is based in Alpharetta, Georgia. Inhibitex, Inc., a biopharmaceutical company, develops differentiated anti-infective products to prevent and treat serious infections primarily shingles and chronic hepatitis C. Its anti- infective product candidates include FV-100, an orally available nucleoside analogue prodrug, which completed Phase I trials used for the treatment of herpes zoster or shingles; and aurexis, a humanized monoclonal antibody, which completed Phase IIa trials used for the treatment of serious S. aureus infections. The company's preclinical product candidates include HCV polymerase inhibitors, which are used for the treatment of chronic HCV infection; HIV integrase inhibitors that are used for the treatment of HIV infection; and staphylococcal vaccines, an active vaccine to prevent S. aureus infections. It has MSCRAMM based license and collaboration agreement with Wyeth Pharmaceuticals for the development of staphylococcal vaccines; and royalty-bearing license agreement with Cardiff University and Katholieke Universiteit for intellectual property of HCV nucleoside polymerase inhibitors.

China Shineway Pharmaceutical Group Limited company develops, manufactures, and sells modern Chinese medicines and western pharmaceuticals. Three of its principal products are Xin Nao Qing soft capsules, Qingkailing injection, and Shenmai injection -- the company's production of these three products is the largest in China. Shineway has plans to expand its sales and marketing network, focusing on hospitals and retail pharmacies to expand its market coverage and deepen its market penetration. Chairman Li Zhenjiang and his family control more than 70% of the company.

AMAG Pharmaceuticals, Inc. company was founded in 1981 and is based in Lexington, Massachusetts. AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States, Europe, and Japan. It also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Feraheme, an iron replacement therapeutic agent for the treatment of iron deficiency anemia and used as a diagnostic agent for vascular enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease; and GastroMARK used for delineating the bowel in MRI. AMAG Pharmaceuticals products also include Combidex, an investigational functional molecular imaging agent.

Luitpold Pharmaceuticals earns its gold from the businesses of drugs and medical devices. Luitpold markets and manufactures injectable products used to treat an array of ailments including kidney disease. Luitpold also manufactures materials used in dental bone grafting and bone regeneration and treatments for equine and canine joint diseases. The company, which targets its products primarily to hospitals and clinics in US and Canadian markets, operates through four divisions: American Regent, Luitpold Animal Health, Osteohealth, and Contract Manufacturing. Originally a German company named after a Bavarian prince, Luitpold is a subsidiary of one of Japan's largest pharmaceutical companies, Daiichi Sankyo.

Ash Stevens, Inc. was founded in 1962 to provide chemical research for the government and later branched out into the private sector. Ash Stevens, Inc. company, a contract pharmaceutical manufacturer develops and manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies. It also supports clinical drug trials and helps others navigate the FDA's regulatory maze. Its customers include the federal government and commercial pharmaceutical firms. The company's portfolio includes about a dozen FDA-approved drug components.

Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, rheumatology, anesthesia, and antidotes in the United States. The company's Ophthalmic Segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting. It also sells therapeutic products, such as antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers and other national account customers. In addition, this segment offers non-pharmaceutical products, including various artificial tear solutions, preservative-free lubricating ointments, eyelid cleansers, vitamin supplements, and contact lens accessories. The company's Hospital Drugs and Injectables Segment markets specialty injectable pharmaceutical products, including antidotes and anesthesia, as well as products used in the treatment of rheumatoid arthritis and pain management. It markets products to hospitals through wholesalers and other national account customers, as well as directly to medical specialists. The company's Biologics and Vaccines Segment markets adult Tetanus-Diphtheria vaccines directly to hospitals and physicians, as well as through wholesalers and national distributors. Its Contract Services Segment manufactures products for third party pharmaceutical and biotechnology customers. The company also markets and distributes vaccines purchased from outside sources. Its customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and other pharmaceutical companies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.